Adjustment to Net Income (Loss): Mark to Market Available-for-sale Securities
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Adjusted Profitability Ratios: Mark to Market Available-for-sale Securities (Summary)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Profitability ratio | Description | The company |
---|---|---|
Adjusted net profit margin | An indicator of profitability, calculated as adjusted net income divided by revenue. | Vertex Pharmaceuticals Inc. adjusted net profit margin ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023. |
Adjusted ROE | A profitability ratio calculated as adjusted net income divided by shareholders’ equity. | Vertex Pharmaceuticals Inc. adjusted ROE improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Adjusted ROA | A profitability ratio calculated as adjusted net income divided by total assets. | Vertex Pharmaceuticals Inc. adjusted ROA improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Vertex Pharmaceuticals Inc., Profitability Ratios: Reported vs. Adjusted
Adjusted Net Profit Margin
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
2023 Calculations
1 Net profit margin = 100 × Net income ÷ Revenues
= 100 × 3,619,600 ÷ 9,869,200 = 36.68%
2 Adjusted net profit margin = 100 × Adjusted net income ÷ Revenues
= 100 × 3,629,300 ÷ 9,869,200 = 36.77%
Profitability ratio | Description | The company |
---|---|---|
Adjusted net profit margin | An indicator of profitability, calculated as adjusted net income divided by revenue. | Vertex Pharmaceuticals Inc. adjusted net profit margin ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023. |
Adjusted Return on Equity (ROE)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
2023 Calculations
1 ROE = 100 × Net income ÷ Shareholders’ equity
= 100 × 3,619,600 ÷ 17,580,400 = 20.59%
2 Adjusted ROE = 100 × Adjusted net income ÷ Shareholders’ equity
= 100 × 3,629,300 ÷ 17,580,400 = 20.64%
Profitability ratio | Description | The company |
---|---|---|
Adjusted ROE | A profitability ratio calculated as adjusted net income divided by shareholders’ equity. | Vertex Pharmaceuticals Inc. adjusted ROE improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Adjusted Return on Assets (ROA)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
2023 Calculations
1 ROA = 100 × Net income ÷ Total assets
= 100 × 3,619,600 ÷ 22,730,200 = 15.92%
2 Adjusted ROA = 100 × Adjusted net income ÷ Total assets
= 100 × 3,629,300 ÷ 22,730,200 = 15.97%
Profitability ratio | Description | The company |
---|---|---|
Adjusted ROA | A profitability ratio calculated as adjusted net income divided by total assets. | Vertex Pharmaceuticals Inc. adjusted ROA improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |